PDF(Pubmed)
Abstract：
There are limited information on outcome, complications and treatments of critically ill COVID-19 patients requiring admission to an intensive care unit (ICU). The aim of this study is to describe the clinical ICU course, treatments used, complications and outcomes, of critically ill COVID-19 patients admitted in seven ICU in Galicia region during the 2020 March-April pandemic peak.
Between March 21 and April 19, 2020, we evaluated critically ill COVID-19 patients admitted to the ICU of Anesthesia of seven hospitals in Galicia, northwestern Spain. Outcome, complications, and treatments were monitored until May 6, 2020, the final date of follow-up.
A total of 97 critically ill COVID-19 patients were included. During ICU stay, mechanical ventilation became necessary in 80 (82.5%) patients, and tracheostomy in 22 (22.7%) patients. Prone position was used frequently in both intubated (67.5%) and awake (27.8%) patients. Medications consisted of antivirals agents (92.7%), corticosteroids (93.8%), tocilizumab (57.7%), and intermediate or high doses of anticoagulants (83.5%). The most frequent complications were ICU-acquired infection (52.6%), thrombosis events (16.5%), and reintubation (9.3%). After a median follow-up of 42 (34-45) days, 15 patients (15.5%) deceased, 73 patients (75.2%) had been discharged from ICU, and nine patients (9.3%) were still in the ICU.
A high proportion of our critically ill COVID-19 patients required mechanical ventilation, prone positioning, antiviral medication, corticosteroids, and anticoagulants. ICU complications were frequent, mainly infections and thrombotic events. We had a relatively low mortality of 15,5%.
Between March 21 and April 19, 2020, we evaluated critically ill COVID-19 patients admitted to the ICU of Anesthesia of seven hospitals in Galicia, northwestern Spain. Outcome, complications, and treatments were monitored until May 6, 2020, the final date of follow-up.
A total of 97 critically ill COVID-19 patients were included. During ICU stay, mechanical ventilation became necessary in 80 (82.5%) patients, and tracheostomy in 22 (22.7%) patients. Prone position was used frequently in both intubated (67.5%) and awake (27.8%) patients. Medications consisted of antivirals agents (92.7%), corticosteroids (93.8%), tocilizumab (57.7%), and intermediate or high doses of anticoagulants (83.5%). The most frequent complications were ICU-acquired infection (52.6%), thrombosis events (16.5%), and reintubation (9.3%). After a median follow-up of 42 (34-45) days, 15 patients (15.5%) deceased, 73 patients (75.2%) had been discharged from ICU, and nine patients (9.3%) were still in the ICU.
A high proportion of our critically ill COVID-19 patients required mechanical ventilation, prone positioning, antiviral medication, corticosteroids, and anticoagulants. ICU complications were frequent, mainly infections and thrombotic events. We had a relatively low mortality of 15,5%.
摘要：
关于结果的信息有限，需要入住重症监护病房（ICU）的危重COVID-19患者的并发症和治疗。这项研究的目的是描述临床ICU课程，使用的治疗方法，并发症和结果，在2020年3月至4月大流行高峰期间，加利西亚地区7名ICU收治的危重COVID-19患者。
在2020年3月21日至4月19日之间，我们评估了加利西亚七家医院麻醉ICU收治的重症COVID-19患者，西班牙西北部。结果,并发症,和治疗监测，直到2020年5月6日，随访的最后日期。
共纳入97例重症COVID-19患者。ICU入住期间,80例（82.5%）患者需要机械通气，22例（22.7%）患者行气管切开术。插管（67.5％）和清醒（27.8％）的患者都经常使用俯卧位。药物包括抗病毒药物（92.7％），皮质类固醇（93.8%），托珠单抗（57.7%），和中等或高剂量的抗凝剂（83.5%）。最常见的并发症是ICU获得性感染（52.6%），血栓事件（16.5%），和再插管(9.3%)。经过42（34-45）天的中位随访，15名患者（15.5%）死亡，73例患者（75.2%）已从ICU出院，9例患者(9.3%)仍在ICU.
我们的重症COVID-19患者中有很大比例需要机械通气，俯卧定位，抗病毒药物,皮质类固醇,和抗凝剂。ICU并发症频繁，主要是感染和血栓事件。我们的死亡率相对较低，为15.5%。
在2020年3月21日至4月19日之间，我们评估了加利西亚七家医院麻醉ICU收治的重症COVID-19患者，西班牙西北部。结果,并发症,和治疗监测，直到2020年5月6日，随访的最后日期。
共纳入97例重症COVID-19患者。ICU入住期间,80例（82.5%）患者需要机械通气，22例（22.7%）患者行气管切开术。插管（67.5％）和清醒（27.8％）的患者都经常使用俯卧位。药物包括抗病毒药物（92.7％），皮质类固醇（93.8%），托珠单抗（57.7%），和中等或高剂量的抗凝剂（83.5%）。最常见的并发症是ICU获得性感染（52.6%），血栓事件（16.5%），和再插管(9.3%)。经过42（34-45）天的中位随访，15名患者（15.5%）死亡，73例患者（75.2%）已从ICU出院，9例患者(9.3%)仍在ICU.
我们的重症COVID-19患者中有很大比例需要机械通气，俯卧定位，抗病毒药物,皮质类固醇,和抗凝剂。ICU并发症频繁，主要是感染和血栓事件。我们的死亡率相对较低，为15.5%。
